{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:05:33Z","timestamp":1784995533037,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HEC Forum"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10730-025-09574-5","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:58:08Z","timestamp":1770893888000},"page":"315-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating Ethical Challenges in CAR-T Treatment"],"prefix":"10.1007","volume":"38","author":[{"given":"Elise R. A.","family":"Pennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Spanjaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Ruth","family":"Schaaphok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein A.","family":"van Maanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-6477","authenticated-orcid":false,"given":"Suzanne","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"15","key":"9574_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1182\/blood.2023020703","volume":"142","author":"JA Bell","year":"2023","unstructured":"Bell, J. A., Jeffries, G. A., & Chen, C. I. (2023). Mitigating inequity: Ethically prioritizing patients to CAR T-cell therapy. Blood, 142(15), 1263\u20131270.","journal-title":"Blood"},{"issue":"3","key":"9574_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.54","volume":"8","author":"P Berning","year":"2024","unstructured":"Berning, P., Shumilov, E., Maulhardt, M., Boyadzhiev, H., Kerkhoff, A., Call, S., Reicherts, C., Saidy, A. O., Aydilek, E., & Hoffmann, M. (2024). Chimeric antigen receptor\u2010T cell therapy shows similar efficacy and toxicity in patients with diffuse large B\u2010cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study. Hemasphere, 8(3), Article e54.","journal-title":"Hemasphere"},{"issue":"6","key":"9574_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1370\/afm.1713","volume":"12","author":"T Bodenheimer","year":"2014","unstructured":"Bodenheimer, T., & Sinsky, C. (2014). From triple to quadruple aim: Care of the patient requires care of the provider. The Annals of Family Medicine, 12(6), 573\u2013576.","journal-title":"The Annals of Family Medicine"},{"issue":"6","key":"9574_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews Clinical Oncology, 20(6), 359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"12","key":"9574_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.2023020197","volume":"142","author":"D Chihara","year":"2023","unstructured":"Chihara, D., Liao, L., Tkacz, J., Franco, A., Lewing, B., Kilgore, K. M., Nastoupil, L. J., & Chen, L. (2023). Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood, 142(12), 1047\u20131055.","journal-title":"Blood"},{"issue":"9","key":"9574_CR6","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., & Subklewe, M. (2024). A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature Medicine, 30(9), 2667\u20132678.","journal-title":"Nature Medicine"},{"issue":"16","key":"9574_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., & Zhu, L. (2017). Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood, 130(16), 1800\u20131808.","journal-title":"Blood"},{"issue":"1","key":"9574_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijnurstu.2012.08.017","volume":"50","author":"AJ de Veer","year":"2013","unstructured":"de Veer, A. J., Francke, A. L., Struijs, A., & Willems, D. L. (2013). Determinants of moral distress in daily nursing practice: A cross sectional correlational questionnaire survey. International Journal of Nursing Studies, 50(1), 100\u2013108.","journal-title":"International Journal of Nursing Studies"},{"issue":"4","key":"9574_CR9","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham, C. E., Velasco, R., Tomas, A. A., Stewart, O. P., Dachy, G., Del Bufalo, F., Doglio, M., Henter, J.-I., Ort\u00ed, G., & Peric, Z. (2025). Non-ICANS neurological complications after CAR T-cell therapies: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee. The Lancet Oncology, 26(4), e203\u2013e213.","journal-title":"The Lancet Oncology"},{"issue":"7","key":"9574_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"I Hernandez","year":"2018","unstructured":"Hernandez, I., Prasad, V., & Gellad, W. F. (2018). Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncology, 4(7), 994\u2013996.","journal-title":"JAMA Oncology"},{"issue":"4","key":"9574_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.18609\/cgti.2018.030","volume":"4","author":"K Imbach","year":"2018","unstructured":"Imbach, K., Patel, A., & Levine, A. D. (2018). Ethical considerations in the translation of CAR-T cell therapies. Cell Gene Therapy Insights, 4(4), 295\u2013307.","journal-title":"Cell Gene Therapy Insights"},{"issue":"10","key":"9574_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/amajethics.2019.913","volume":"21","author":"G Inguaggiato","year":"2019","unstructured":"Inguaggiato, G., Metselaar, S., Molewijk, B., & Widdershoven, G. (2019). How moral case deliberation supports good clinical decision making. AMA Journal of Ethics, 21(10), 913\u2013919.","journal-title":"AMA Journal of Ethics"},{"key":"9574_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","volume":"30","author":"PC Johnson","year":"2024","unstructured":"Johnson, P. C., Neckermann, I., Sadrzadeh, H., Newcomb, R., El-Jawahri, A. R., & Frigault, M. J. (2024). Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T-cell therapy. Transplantation and Cellular Therapy, 30, 490\u2013499.","journal-title":"Transplantation and Cellular Therapy"},{"issue":"1","key":"9574_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. The New England Journal of Medicine, 379(1), 64\u201373.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"9574_CR15","first-page":"1","volume":"17","author":"J Kaur","year":"2011","unstructured":"Kaur, J., & Mohanti, B. K. (2011). Transition from curative to palliative care in cancer. Indian Journal of Palliative Care, 17(1), 1.","journal-title":"Indian Journal of Palliative Care"},{"issue":"4","key":"9574_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/10428194.2024.2436606","volume":"66","author":"K Kim","year":"2025","unstructured":"Kim, K., & Chihara, D. (2025). The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma. Leukemia and Lymphoma, 66(4), 617\u2013627.","journal-title":"Leukemia and Lymphoma"},{"issue":"4","key":"9574_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"T Kourelis","year":"2023","unstructured":"Kourelis, T., Bansal, R., Berdeja, J., Siegel, D., Patel, K., Mailankody, S., Htut, M., Shah, N., Wong, S. W., & Sidana, S. (2023). Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: A multi-institution experience. Transplantation and Cellular Therapy, 29(4), 255\u2013258.","journal-title":"Transplantation and Cellular Therapy"},{"issue":"1","key":"9574_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1359105315595120","volume":"22","author":"G Lamiani","year":"2017","unstructured":"Lamiani, G., Borghi, L., & Argentero, P. (2017). When healthcare professionals cannot do the right thing: A systematic review of moral distress and its correlates. Journal of Health Psychology, 22(1), 51\u201367.","journal-title":"Journal of Health Psychology"},{"issue":"8","key":"9574_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40266-023-01047-z","volume":"40","author":"JE Maakaron","year":"2023","unstructured":"Maakaron, J. E., & William, B. M. (2023). Age is no barrier: CAR-T therapy in older adults. Drugs and Aging, 40(8), 685\u2013689.","journal-title":"Drugs and Aging"},{"issue":"2","key":"9574_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1377\/hlthaff.2010.0100","volume":"30","author":"MD McHugh","year":"2011","unstructured":"McHugh, M. D., Kutney-Lee, A., Cimiotti, J. P., Sloane, D. M., & Aiken, L. H. (2011). Nurses\u2019 widespread job dissatisfaction, burnout, and frustration with health benefits signal problems for patient care. Health Affairs, 30(2), 202\u2013210.","journal-title":"Health Affairs"},{"issue":"7\u20138","key":"9574_CR21","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/09697330221074014","volume":"29","author":"S Metselaar","year":"2022","unstructured":"Metselaar, S., van Schaik, M., Widdershoven, G., & Pasman, H. R. (2022). CURA: A clinical ethics support instrument for caregivers in palliative care. Nursing Ethics, 29(7\u20138), 1562\u20131577.","journal-title":"Nursing Ethics"},{"issue":"2","key":"9574_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/jme.2006.018580","volume":"34","author":"AC Molewijk","year":"2008","unstructured":"Molewijk, A. C., Abma, T., Stolper, M., & Widdershoven, G. (2008). Teaching ethics in the clinic. The theory and practice of moral case deliberation. Journal of Medical Ethics, 34(2), 120\u2013124.","journal-title":"Journal of Medical Ethics"},{"issue":"1","key":"9574_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6939-16-4","volume":"16","author":"B Molewijk","year":"2015","unstructured":"Molewijk, B., Hem, M. H., & Pedersen, R. (2015). Dealing with ethical challenges: A focus group study with professionals in mental health care. BMC Medical Ethics, 16(1), 1\u201312.","journal-title":"BMC Medical Ethics"},{"issue":"3","key":"9574_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0969733017724354","volume":"26","author":"G Morley","year":"2019","unstructured":"Morley, G., Ives, J., Bradbury-Jones, C., & Irvine, F. (2019). What is \u2018moral distress\u2019? A narrative synthesis of the literature. Nursing Ethics, 26(3), 646\u2013662.","journal-title":"Nursing Ethics"},{"issue":"1","key":"9574_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., & Daver, N. (2018). Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nature Reviews Clinical Oncology, 15(1), 47\u201362.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"19","key":"9574_CR25","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., & Timmerman, J. M. (2023). Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 141(19), 2307\u20132315.","journal-title":"Blood"},{"issue":"10","key":"9574_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/medethics-2012-100546","volume":"38","author":"M Plantinga","year":"2012","unstructured":"Plantinga, M., Molewijk, B., de Bree, M., Moraal, M., Verkerk, M., & Widdershoven, G. A. M. (2012). Training healthcare professionals as moral case deliberation facilitators: Evaluation of a Dutch training programme. Journal of Medical Ethics, 38(10), 630\u2013635.","journal-title":"Journal of Medical Ethics"},{"issue":"10","key":"9574_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., & Chabannon, C. (2023). Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood, 142(10), 865\u2013877.","journal-title":"Blood"},{"key":"9574_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03813-5","author":"K Rejeski","year":"2025","unstructured":"Rejeski, K., Hill, J. A., Dahiya, S., & Jain, M. D. (2025). Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nature Medicine , 31, 2132\u20132146. https:\/\/doi.org\/10.1038\/s41591-025-03813-5","journal-title":"Nature Medicine"},{"issue":"4","key":"9574_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1191\/0269216306pm1156oa","volume":"20","author":"P Schofield","year":"2006","unstructured":"Schofield, P., Carey, M., Love, A., Nehill, C., & Wein, S. (2006). \u2018Would you like to talk about your future treatment options?\u2019 Discussing the transition from curative cancer treatment to palliative care. Palliative Medicine, 20(4), 397\u2013406.","journal-title":"Palliative Medicine"},{"key":"9574_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12910-021-00700-9","volume":"22","author":"G Schofield","year":"2021","unstructured":"Schofield, G., Dittborn, M., Selman, L. E., & Huxtable, R. (2021). Defining ethical challenge (s) in healthcare research: A rapid review. BMC Medical Ethics, 22, 1\u201317.","journal-title":"BMC Medical Ethics"},{"issue":"9","key":"9574_CR32","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn, L. H., & Salles, G. (2021). Diffuse large B-cell lymphoma. The New England Journal of Medicine, 384(9), 842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"9574_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009793","volume":"13","author":"L Shune","year":"2025","unstructured":"Shune, L., Frigault, M. J., & Riedell, P. A. (2025). CAR-T cell therapy in older adults with relapsed\/refractory LBCL: Benefits and challenges. Journal for ImmunoTherapy of Cancer, 13(6), Article e009793.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"3","key":"9574_CR34","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1200\/OP.22.00501","volume":"19","author":"AM Spanjaart","year":"2022","unstructured":"Spanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., Van Meerten, T., Van Doesum, J. A., Minnema, M. C., Jak, M., & Van Dorp, S. (2022). Development of a core set of patient-and caregiver-reported signs and symptoms to facilitate early recognition of acute chimeric antigen receptor T-cell therapy toxicities. JCO Oncology Practice, 19(3), e407\u2013e416.","journal-title":"JCO Oncology Practice"},{"issue":"17","key":"9574_CR35","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/cancers15174334","volume":"15","author":"AM Spanjaart","year":"2023","unstructured":"Spanjaart, A. M., Pennings, E. R. A., Mutsaers, P. G. N. J., van Dorp, S., Jak, M., van Doesum, J. A., de Boer, J. W., Niezink, A. G. H., Kos, M., & Vermaat, J. S. P. (2023). The Dutch CAR-T tumorboard experience: Population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in The Netherlands. Cancers, 15(17), 4334.","journal-title":"Cancers"},{"key":"9574_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12910-016-0125-1","volume":"17","author":"M Stolper","year":"2016","unstructured":"Stolper, M., Molewijk, B., & Widdershoven, G. (2016). Bioethics education in clinical settings: Theory and practice of the dilemma method of moral case deliberation. BMC Medical Ethics, 17, 1\u201310.","journal-title":"BMC Medical Ethics"},{"key":"9574_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3200","author":"A Sureda","year":"2023","unstructured":"Sureda, A., Lugtenburg, P. J., Kersten, M. J., Subklewe, M., Spanjaart, A., Shah, N. N., Kerbauy, L. N., Roddie, C., Pennings, E. R. A., & Mahuad, C. (2023). Cellular therapy in lymphoma. Hematological Oncology , 42(6), e3200. https:\/\/doi.org\/10.1002\/hon.3200","journal-title":"Hematological Oncology"},{"issue":"3","key":"9574_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/practneurol-2017-001740","volume":"18","author":"DYB Tan","year":"2018","unstructured":"Tan, D. Y. B., Ter Meulen, B. C., Molewijk, A., & Widdershoven, G. (2018). Moral case deliberation. Practical Neurology, 18(3), 181\u2013186.","journal-title":"Practical Neurology"},{"key":"9574_CR39","first-page":"37","volume-title":"Clinical ethics consultation","author":"G Widdershoven","year":"2016","unstructured":"Widdershoven, G., & Molewijk, B. (2016). Philosophical foundations of clinical ethics: A hermeneutic perspective. In J.-S. Gordon (ed.),Clinical ethics consultation (pp. 37\u201352). Routledge."}],"container-title":["HEC Forum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10730-025-09574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10730-025-09574-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10730-025-09574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:41:38Z","timestamp":1784994098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10730-025-09574-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9574"],"URL":"https:\/\/doi.org\/10.1007\/s10730-025-09574-5","relation":{},"ISSN":["0956-2737","1572-8498"],"issn-type":[{"value":"0956-2737","type":"print"},{"value":"1572-8498","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SHT received honoraria from and has a consulting\/advisory role for Takeda, Roche, and BMS (all paid to the institution). MTK has a consulting\/advisory role for CellPoint. MJK received honoraria from and has a consulting\/advisory role for BMS\/Celgene, Kite, a Gilead Company, Miltenyi Biotec, Galapagos, Novartis, Adicet Bio, Mustang Bio, Janssen, AbbVie and Roche, research funding from Kite, a Gilead Company, and travel support from AbbVie and Janssen (all to institution). ERAP, AMS, ARS, MAvM and SM declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethics Review Committee of the Academic Medical Center.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained to participate in the study, audio record the session and for publication of the case example.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}